Navigation Links
RNL BIO Co. Ltd. stellt IND-Antrag, um klinische Phase-II-Studie des RNL-JointStem gegen Arthrose in den Vereinigten Staaten einzuleiten
Date:5/3/2013

rging, ist einer der größten Vorteile in der Tatsache zu sehen, dass das Produkt im Gegensatz zu vielen anderen invasiven Eingriffen, die derzeit zur Behandlung von AD eingesetzt werden, nur ein einziges Mal injiziert werden muss. „Die Behandlung dieser schmerzvollen chronischen Erkrankung sollte den Schmerz lindern und nicht verstärken", so Dr. Ra. „Wir hoffen nachzuweisen, dass RNL-JointStem wirksam zur Knorpelregeneration, Schmerzlinderung und Verbesserung der Gelenkfunktion von AD-Patienten beiträgt, und hoffen auf eine angemessen zeitnahe Marktzulassung."

Im Zuge der klinischen Studie wird RNL-JointStem mit bestehenden Verfahrensweisen auf Basis von Hyaluronsäure (HA) verglichen. Die Patientengruppe wird bei dieser klinischen Studie neben Patienten mit Arthrose-Befund auch weitere Patienten umfassen, deren Ärzte der Ansicht sind, dass sie die entsprechenden Teilnahmevoraussetzungen erfüllen. Der Zielmarkt für RNL-JointStem sind Patienten im Alter von unter 60 Jahren, für die derzeit keine wirksame Therapieoption besteht.

Informationen zu Arthrose

Die degenerative Arthritis ist die häufigste Form der Arthritis. Schätzungen zufolge leiden 26,9 Millionen Amerikaner ab einem Alter von 25 Jahren an degenerativer Arthritis bestimmter Gelenke. In älteren Bevölkerungsschichten ist der prozentuale Anteil des Krankheitsbefalls entsprechend höher. Zu den klinischen Manifestationen der Krankheit zählen Gelenkschmerz und Bewegungsbeeinträchtigung. Überdies ist das umliegende Gewebe häufig von lokalen Entzündungen befallen. Die Krankheitsursache der degenerativen Arthritis ist nicht vollständig erforscht. Verletzungen, Alter und die genetische Veranlagung gelten jedoch als Risikofaktoren.

Die degenerative Arthritis ist eine Krankheit, die progre
'/>"/>

SOURCE RNL BIO
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Taiho Pharmaceutical stellt Zulassungsantrag zur Herstellung und Vermarktung des neuartigen Antitumormittels TAS-102
2. Dr. Joachim Schorr (PhD) zum Chief Scientific Officer von Caris Life Sciences bestellt
3. Harvest Technologies Corporation erhält CE-Kennzeichnung für erweiterte klinische Indikation zur Behandlung nicht optionaler kritischer Extremitätenischämie
4. Charleston Laboratories, Inc. beginnt mit klinischer Phase 3-Studie für CL-108
5. IDEV gibt Ergebnisse von Studie zur Revaskularisation mit Supera an echten Patienten (RESTORE) bekannt - Studie demonstriert positive klinische Ergebnisse bei schwerkranken Patienten mit langen Läsionen
6. Neue klinische Richtlinien für ältere Patienten mit Typ 2 Diabetes, um einen europaweiten Pflegenotstand zu verhindern
7. MR Solutions bringt vollständige Reihe heliumfreier präklinischer Magnetresonanztomographen auf den Markt
8. Neuartige Krebsimmuntherapie für den Beginn klinischer Studien bereit
9. Acutus Medical, Inc. erprobt erstmals seinen Echtzeit-3D-Bildgebungskatheter von CT/MRI-Qualität in einer klinischen Studie am Menschen
10. RNL BIO Co. Ltd. Files IND To Commence Phase II Clinical Trial Of RNL-JointStem For Osteoarthritis In The United States
11. RNL BIO Co. Ltd. lämnar in IND-ansökan om att påbörja klinisk fas II-prövning av RNL-JointStem för artros i USA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 MiMedx Group, ... developer, processor and marketer of patent protected regenerative ... announced today that it has entered into a ... MiMedx will provide its dehydrated human amnion/chorion membrane ... non- exclusively on a private label basis. ...
(Date:9/18/2014)... 18, 2014  Halozyme Therapeutics, Inc. (NASDAQ: ... Food and Drug Administration (FDA) has removed the ... PEGPH20 in SWOG,s ongoing Phase 1b/2 clinical trial ... investigational drug PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in ... with metastatic pancreatic adenocarcinoma.  The study will resume ...
(Date:9/18/2014)... -- Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company ... announced today that it has appointed Mr. Christopher ... of Clinical Development. During his extensive career ... successful global clinical operations teams, in the US and ... development of numerous therapeutics and diagnostics across a broad ...
Breaking Medicine Technology:MiMedx Signs Distribution Agreement With Zimmer 2MiMedx Signs Distribution Agreement With Zimmer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2
... (ASX: PGL; Nasdaq: PGLA) today announced additional,data from the ... this,year. This data was presented at the 58th Annual ... Diseases in Boston, USA(1). As the Phase 2 ... data analysis described in this presentation was performed to,evaluate ...
... overall rate of sustained virologic response in ... long-acting interferons in ... Albuferon non-responder study presented at the, Annual Meeting of the American Association for the Study ... ...
Cached Medicine Technology:Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases 2Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases 3Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 2Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 3Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 4Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 5Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 6
(Date:9/18/2014)... (PRWEB) September 18, 2014 It is almost ... sprint or walk for healthier and happier kids. The ... participate in the 4th Annual Miami Children’s Hospital 5K Run/Walk. ... http://www.hyundaihopeonwheels.org , The 5K will take place ... will be outside of Coral Gables City Hall located at ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Clinical trial ... data on the Edema clinical trial scenario. This report ... trials on Edema. It includes an overview of the ... site of trial conduction across the globe. The databook ... their phase, trial status, prominence of the sponsors and ...
(Date:9/18/2014)... PA (PRWEB) September 18, 2014 ... announces the launch of Good Neighbor Pharmacy University, ... access information that will educate and empower pharmacy ... “As the healthcare industry continues to evolve, Good ... as we deliver resources and tools to help ...
(Date:9/18/2014)... September 18, 2014 CD-adapco, the largest ... software, today announced its new partnership with Ben Ainslie ... CD-adapco simulation tool, STAR-CCM+® in the design of its ... participation in the 35th America’s Cup taking place in ... the America’s Cup is sustainability, the set of restrictive ...
(Date:9/18/2014)... more vegetables and drink less sugar, according to a ... it,s still not enough, the study goes on to ... comes to eating healthier at school , The research ... status, may inform a child,s diet. , The study ... education were 85 per cent more likely to eat ...
Breaking Medicine News(10 mins):Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 2Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 3Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 2Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 3Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 4Health News:Good Neighbor Pharmacy University Keeps Pharmacists Ahead of the Curve 2Health News:Ben Ainslie Racing Using STAR-CCM+ Simulation Software to Design 35th America’s Cup Racing Boat 2Health News:Kids eat better if their parents went to college 2
... a study published in the recent issue of Annals ... exercise //as preconditions to prevent and control diabetes type ... cost effective to control diabetes through rigorous exercise and ... diabetes reduces the body’s ability to store calories, resulting ...
... at the annual meeting of the American Academy of Orthopedic ... back pain may be the result of several problems other ... restrict the effect of a surgery. The study that had ... National Spine Network, US, said that patients who had other ...
... 100 patients at an ear , nose and throat clinic ... snoring // shouldn't expect to receive a diagnosis of obstructive ... examination alone instead an overnight sleep testing needs to be ... ,For the study, physicians evaluated the patients with a ...
... now that after delivery depressions, that had plagued new mothers all ... the delivery. As a result of this belief, many pregnant women ... new study that comes in the recent issue of British Medical ... to Deirdre Murphy of Dundee University, who had led the team ...
... twins and their mothers to see if there was a ... // of life and children's antisocial behavior by age 7 ... have increased problems with conduct and more antisocial behavior . ... the twins' birth and the likeliness of antisocial behavior in ...
... to treat agitation in patients with Alzheimer's or dementia, ... findings of a recent study .// ,For ... Twenty-six of the patients received quetiapine (an antipsychotic also ... also known as Exelon), and 29 received a placebo. ...
Cached Medicine News:
... German Craftsmanship have produced the ... world. Ocutek now makes them ... of the coveted Meisterbrief certificate, ... are qualified to become Ocutek ...
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: